J&J's psoriasis drug bests Humira in the clinic but can it compete?

 
• By Lucie Ellis-Taitt

Johnson & Johnson's anti–interleukin-23 therapy, guselkumab, has shown greater efficacy than AbbVie's Humira in a Phase II psoriasis trial – but can it compete in a saturated market place?

More from Dermatological

More from Therapy Areas